- Stocks
- Pharma & Healthcare
- Aptus Pharma
Aptus Pharma share price
NSE: APPLPharma & HealthcareMedical Distribution
Aptus Pharma at a glance
With a market capitalisation of ₹377 Cr, it ranks 1940th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Medical Distribution.
Its return on equity was 19.8% in FY26. Promoters held 72.89% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹377 CrRank 1940 on NSE
- Price to book
- 10.26×FY26
- ROE
- 19.8%FY26
- ROCE
- 29.6%FY26
- Debt to equity
- 0.31FY26
- Net profit margin
- 9.9%FY26
- Book value / share
- ₹34.03FY26
Returns to 19 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Aptus Pharma financials
| Item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Revenue | ₹14 Cr | ₹18 Cr | ₹25 Cr | ₹47 Cr |
| Operating profit | ₹0 Cr | ₹1 Cr | ₹4 Cr | ₹6 Cr |
| Net profit | ₹0 Cr | ₹1 Cr | ₹3 Cr | ₹5 Cr |
| EPS (₹) | ₹1.30 | ₹5.32 | ₹6.37 | ₹7.78 |
| Cash from operations | −₹0 Cr | −₹2 Cr | −₹2 Cr | ₹0 Cr |
| Total debt | ₹2 Cr | ₹4 Cr | ₹3 Cr | ₹1 Cr |
| Shareholders' equity | ₹1 Cr | ₹2 Cr | ₹7 Cr | ₹23 Cr |
Aptus Pharma shareholding pattern
| Holder | 26 Sep 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 19 May 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 72.89% | 72.89% | 72.89% | 72.89% | 72.89% | 72.89% |
| Non-institutions | 14.29% | 14.29% | 27.11% | 27.11% | 27.11% | 27.11% |
Aptus Pharma vs peers
The listed Pharma & Healthcare companies nearest to Aptus Pharma by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| ASARFIAsarfi Hospital | — | — | — | ₹446 Cr | — | — |
| JENBURPHJenburkt Pharma | ₹905.20 | −1.63% | — | ₹399 Cr | 11.5 | — |
| TRANSCHEMTranschem | — | — | — | ₹391 Cr | — | — |
| APPLAptus Pharma | — | — | — | ₹377 Cr | — | — |
| MEDICAMEQMedicamen Biotech | ₹273.35 | −4.09% | −11.6% | ₹371 Cr | 37.9 | — |
| ASTALLTDAstal Lab | — | — | — | ₹358 Cr | — | — |
| AAREYDRUGSAarey Drugs & Pharmaceuticals | ₹114.47 | +1.30% | +39.6% | ₹325 Cr | 82.4 | — |
Ask anything about Aptus Pharma
Pivot answers on the live chart with evidence you can check, and tests strategies against APPL's own history. Try: “Why has APPL moved over the last three months?” · “Backtest a 50-day moving-average crossover on APPL over five years” · “Compare APPL with ASARFI on margins and valuation”
Frequently asked questions about Aptus Pharma
What is the market cap of Aptus Pharma?
Aptus Pharma's market capitalisation is ₹377 Cr (₹377 Cr) at the 19 Oct 2026 close, ranking 1940th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Aptus Pharma?
Return on equity was 19.8% in FY26 and return on capital employed was 29.6% in FY26 (standalone figures).
Is Aptus Pharma a debt-free company?
No. Aptus Pharma's debt-to-equity ratio was 0.31 in FY26, with total debt of ₹1 Cr.
What is the shareholding pattern of Aptus Pharma?
As of 30 Jun 2026: promoters 72.89%, non-institutions 27.11%.
Who are Aptus Pharma's competitors?
The listed Pharma & Healthcare companies closest to Aptus Pharma by market cap are Asarfi Hospital, Jenburkt Pharma, Transchem, Medicamen Biotech, Astal Lab and Aarey Drugs & Pharmaceuticals.
Is Aptus Pharma a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Aptus Pharma's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on APPL against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 19 Oct 2026 (returns and ratios at the 19 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with A · all NSE stocks · this page as text